Carmustine is an alkylating agent used in the treatment of various malignancies, including brain tumours and multiple myeloma, among others. A cell-cycle phase nonspecific alkylating antineoplastic agent.
- Mechanism
- Curator reviewed
Carmustine causes cross-links in DNA and RNA, leading to the inhibition of DNA synthesis, RNA production and RNA translation (protein synthesis). Carmustine also binds to and modifies (carbamoylates) glutathione reductase. This leads to cell death.
- Primary indication
- For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.Curator reviewed · 12 structured indications
- Formula / weight
- C5H9Cl2N3O2 · 214.05 g/mol (avg)
- First approval
- Canada, 2011 · United States, 1996 · European Union, 2020
- Also known as
- BCNU · bis-chloroethylnitrosourea · Bis(chloroethyl) nitrosourea · Bischloroethyl nitrosourea
- Code names
- DTI-015 · FDA-0345 · NSC-409962 · SK-27702 · SRI-1720 · WR-139021
- Brand names
Resolves to
Clinical / RWD
Structure
InChIKey
DLGOEMSEDOSKAD-UHFFFAOYSA-NSMILESClCCNC(=O)N(CCCl)N=OTargets
What you can answer from here — as of September 23, 2026
3Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Carmustine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account